Today, for National Psoriasis Awareness Month (every August), we have a rundown of five of the latest upcoming and currently recruiting, phase 3, interventional clinical trials focused on plaque psoriasis medications. Because plaque psoriasis can severely impact a patient’s quality of life, along with potentially leading to comorbidities, the development of effective plaque psoriasis medications is critical.
This rundown represents some of the many ongoing clinical trials related to psoriasis, along with a few trials that are just getting started. All of the trials featured in the rundown are based in the United States. The list is accurate as of August 15, 2025.
New in 2025, Phase 3 Clinical Trials for Plaque Psoriasis
| Study Title | Recruiting? | Enrollment | Start Date | Last Update Posted |
|---|---|---|---|---|
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | Not Yet | 3040 (estimated) | 10/30/2025 (estimated) | N/A |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis | Not Yet | 366 (estimated) | 8/26/2025 (estimated) | N/A |
| A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis | Yes | 600 (estimated) | 7/9/2025 | 8/12/2025 |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Yes | 675 (estimated) | 4/15/2025 | 7/18/2025 |
| Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Yes | 1680 (estimated) | 1/8/2025 | 8/3/2025 |
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- Sponsor: Bristol-Myers Squibb
- Goal: A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis.
- Interventions: Deucravacitinib, Ustekinumab.
- Primary Outcome Measures: Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization.
- Timeframe: Up to five years.
- Study Details
- Source
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis (POETYK-PsO-Ped)
- Sponsor: Bristol-Myers Squibb
- Goal: The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis.
- Interventions: Deucravacitinib, placebo.
- Primary Outcome Measures: Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75); Number of participants achieving a static Physicians Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline.
- Timeframe: At week 16; At week 16.
- Study Details
- Source
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
- Sponsor: Takeda
- Goal: The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis.
- Interventions: Zasocitinib, Deucravacitinib, placebo to match zasocitinib, placebo to match deucravacitinib.
- Primary Outcome Measures: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16.
- Timeframe: At week 16.
- Study Details
- Source
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ASCEND)
- Sponsor: Janssen Research & Development
- Goal: The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
- Interventions: JNJ-77242113 and matching placebo, Ustekinumab and matching placebo.
- Primary Outcome Measures: JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16; JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16.
- Timeframe: Week 16; Week 16.
- Study Details
- Source
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis (ONWARD3)
- Sponsor: Alumis
- Goal: The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time.
- Interventions: Open-label ESK-001, Blinded ESK-001, polacebo.
Primary Outcome Measures: To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study. - Timeframe: Approximately four years.
- Study Details
- Source
Related Guidelines:
Management and Treatment of Psoriasis with Topical Therapy and Alternative Medicine Modalities for Psoriasis Severity Measures
Management Of Psoriasis With Systemic Nonbiologic Therapies
Management and Treatment of Psoriasis in Pediatric Patients
Regular investigation into emerging plaque psoriasis clinical trial data enables clinicians to optimize treatment strategies for their patients with plaque psoriasis.
Sign up for alerts and stay informed on more clinical trial rundowns and the latest clinical guideline updates.
Copyright © 2025 Guideline Central, all rights reserved.